129 related articles for article (PubMed ID: 36517408)
1. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.
Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Nguyen MN; Kim HL; Gulley JL; Sater HA; Jamieson C; Hsu CH; Wojtowicz M; House M; Schlom J; Donahue RN; Dahut WL; Madan RA; Bailey S; Centuori S; Bauman JE; Parnes HL; Chow HS
Eur Urol Focus; 2023 May; 9(3):447-454. PubMed ID: 36517408
[TBL] [Abstract][Full Text] [Related]
2. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
[TBL] [Abstract][Full Text] [Related]
3. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
[TBL] [Abstract][Full Text] [Related]
7. Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
[TBL] [Abstract][Full Text] [Related]
8. Development of PROSTVAC immunotherapy in prostate cancer.
Singh P; Pal SK; Alex A; Agarwal N
Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
[TBL] [Abstract][Full Text] [Related]
9. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Madan RA; Arlen PM; Mohebtash M; Hodge JW; Gulley JL
Expert Opin Investig Drugs; 2009 Jul; 18(7):1001-11. PubMed ID: 19548854
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
12. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
Shore ND; Renzulli J; Fleshner NE; Hollowell CMP; Vourganti S; Silberstein J; Siddiqui R; Hairston J; Elsouda D; Russell D; Cooperberg MR; Tomlins SA
JAMA Oncol; 2022 Aug; 8(8):1128-1136. PubMed ID: 35708696
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.
DiPaola RS; Plante M; Kaufman H; Petrylak DP; Israeli R; Lattime E; Manson K; Schuetz T
J Transl Med; 2006 Jan; 4():1. PubMed ID: 16390546
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
19. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
